TriSalus Life Sciences is a technology company.
TriSalus Life Sciences has raised $39.0M across 3 funding rounds.
TriSalus Life Sciences has raised $39.0M in total across 3 funding rounds.
TriSalus Life Sciences has raised $39.0M in total across 3 funding rounds.
TriSalus Life Sciences's investors include Buff Gold Ventures, Versant Ventures.
TriSalus Life Sciences is a clinical-stage biotech company developing innovative drug delivery technology and immunotherapies for liver and pancreatic tumors, which are notoriously difficult to treat due to high intratumoral pressure and immunosuppressive environments.[1][2][4] Its core product, the TriNav Infusion System using proprietary Pressure-Enabled Drug Delivery (PEDD), enhances therapy penetration in over 18,000 procedures by modulating pressure and flow to bypass intravascular barriers; the company also pursues investigational immunotherapy like SD-101, combined with checkpoint inhibitors, targeting solid tumors in these organs.[1][2] TriSalus serves patients with limited treatment options, oncologists, and hospitals, addressing poor drug delivery and immune suppression to potentially transform outcomes in primary liver and pancreatic cancers, with ongoing Phase 1 trials and a 510(k)-cleared pancreatic system signaling growth momentum.[1][2]
TriSalus Life Sciences was founded to pioneer disruptive drug delivery for liver and pancreatic tumors, assembling a team of innovators, engineers, MDs, and scientists from pharma, biotech, and top academic institutions.[1][3] While specific founding year and founders are not detailed in available sources, leadership includes CEO Jodi Cooksey, who previously turned around AltaThera Pharmaceuticals—raising funds, securing FDA indications, and accelerating revenue—after 21 years at Abbott/AbbVie in pipeline planning and global launches.[1] The company's emergence stems from recognizing PEDD's potential, proven in thousands of procedures, evolving into an integrated platform pairing delivery tech with immunotherapies like SD-101 to reprogram immunosuppressive tumor microenvironments.[2][4] Pivotal early traction includes FDA clearances and clinical advancement amid a push for immuno-oncology in hard-to-treat solid tumors.[1][2]
TriSalus rides the immuno-oncology wave targeting solid tumors, where traditional therapies fail due to delivery barriers and immune evasion in liver/pancreas cancers—diseases with dismal prognoses and few options.[2][4] Timing aligns with advances in checkpoint inhibitors and combination therapies, amplified by post-2020 momentum in tumor microenvironment modulation; market forces like rising cancer incidence and demand for precision delivery favor PEDD's organ-specific approach.[1][4] By enabling systemic immunotherapies locally, TriSalus influences the ecosystem, potentially expanding to other solid tumors and partnering with big pharma on acquisitions of complementary agents, reshaping standards for visceral organ oncology.[2]
TriSalus is poised for expansion through Phase 1 readouts, additional FDA milestones, and partnerships pairing PEDD with next-gen immunotherapies, capitalizing on solid tumor trends like multi-mechanism immune reprogramming.[1][2] Evolving regulatory wins and trial data could drive Nasdaq-listed growth (TLSI), with influence growing via ecosystem contributions in delivery tech.[2] As immuno-oncology matures, TriSalus' barrier-breaking platform positions it to deliver breakthroughs for underserved patients, echoing its founding mission to transform liver and pancreatic tumor outcomes.[1][4]
TriSalus Life Sciences has raised $39.0M across 3 funding rounds. Most recently, it raised $15.0M Series C in December 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2015 | $15.0M Series C | Buff Gold Ventures, Versant Ventures | |
| Nov 1, 2013 | $18.0M Series B | Buff Gold Ventures, Versant Ventures | |
| Nov 1, 2011 | $6.0M Series A | Buff Gold Ventures, Versant Ventures |